Popular Pharmaceuticals Limited
Safiul Azam FCMA is currently serving as the Chairman of the Institute Of Cost And Management Accountants Of Bangladesh. In addition to their current role, Safiul Azam FCMA holds various leadership positions at Popular Pharmaceuticals Limited and has previously worked at Brothers Group, Ananda Group, and other organizations in finance and accounting. With a strong educational background in accounting and management, Safiul Azam FCMA brings a wealth of experience and expertise to their current role and has a proven track record in financial management and strategic planning.
This person is not in any offices
Popular Pharmaceuticals Limited
The State of the Art manufacturing facilities of Popular Pharmaceuticals Ltd. (PPL), is located in an industrial area close to the International Airport of the capital city, Dhaka. The total land area of this site is 22,952 m2 with a covered area of 13,509 m2. The manufacturing site is built with strict compliance to WHO cGMP standards and also to meet US FDA and UK MHRA requirements. The project involved an investment of BDT 2,000 M (US$ 30 M approx.); the ever highest initial investment for a pharmaceutical plant in Bangladesh.Through captivating marketing strategies coupled with optimum productivity across all its activities with quality People, Plant and Product, PPL is committed to deliver top tier performance round the year. PPL is continuously investing in diversifying the ranges of products and services to complement the aura with all the major therapeutic areas. PPL aims to create enduring value for the society, and deliver a sustained financial performance that will match the best in the industry. Popular Pharmaceuticals Ltd. intends to focus its skills and resources on all major therapeutic areas that represent majority of the burden of disease profiles of Bangladesh. Popular Pharmaceuticals Ltd. is also committed to delivering new, medically important and commercially successful products to the market every year. Along with its commitment to competitiveness and high performance, PPL will continue to be led by its core values to achieve sustainable success. Efficient pharmaceutical business requires transparent, quality assured processes which are acceptable to regulatory authorities worldwide in addition to the use of complementary new technologies. PPL is committed to the best use of available technology and expertise of the time and thereby ensuring continuous improvements with regards to effectiveness and efficiency.